GNA Biosolutions GmbH, a Munich, Germany-based molecular diagnostics company based in Germany, closed a $13.5M round of financing.
Backers included new investors GreyBird Ventures, Occident, and Wachtumsfonds Bayern, and existing investors SHS Gesellschaft für Beteiligungsmanagement, Robert Bosch Venture Capital, UVC Partners, Mey Capital Matrix, KfW, and btov Partners. Tom Miller, partner at GreyBird Ventures, was the lead investor for the round and will serve as Chairman of GNA’s Board.
The company intends to use the funds to advance development and secure IVD-CE marking of its first Point of Care molecular diagnostic platform.
Led by Federico Buersgens, co-founder and Managing Director, GNA Biosolutions is a private molecular diagnostics company whose proprietary PCA technology offers a molecular diagnostic platform that captures and amplifies nucleic acids from complex clinical samples. PCA assays are being developed for a number of therapeutic areas, including infectious diseases and biothreats.
The company’s first Point of Care product will be utilized for the diagnosis of antibiotic resistant Hospital Acquired Infections (HAIs) and Tuberculosis (TB).
PCA technology has not been cleared or approved by European of U.S. regulatory agencies and is currently for research use only.